Home › Steatotic Liver Disease › NCT07518784

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

Accurate Point of Care Liver Disease Diagnostics

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥ 18 years
* Known or clinically suspected MASLD
* BMI greater than 27 kg/m\^2 and less than 45 kg/m\^2 at the time of referral
* Ability to lie on LiverScope® device table for about 60 minutes
* Ability to hold breath repeatedly for about 20 seconds during MR and LiverScope® exams
* Willing and able to undergo all study procedures

Exclusion Criteria:

* UCSD study personnel or Livivos study personne
* Contraindications to MR
* Potential participant states that she knows that she is pregnant, thinks she may be pregnant, or states that she is trying to become pregnant.
* Known chronic liver disease other than MASLD

About the study

This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use.

In this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations.

Study participants will be asked to complete a one-time visit which includes:

* LiverScope exam * MR exam * FibroScan exam (optional) * Blood draw * Completion of study questionnaires

What is being tested

• LiverScope® exam (diagnostic test)
• MR exam (diagnostic test)
• Blood draw (diagnostic test)
• Body measurements (other)
• Questionnaire (other)

Sponsor: University of California, San Diego · Participants: 26 · Started: Apr 8, 2026

Contact the study team

• Yesenia Covarrubias · Phone: 858-246-2198

Official record on ClinicalTrials.gov — NCT07518784

Locations in the U.S.

Conditions

• Steatotic Liver Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.